Biogen (BIIB) Tops Q4 EPS by 34c, Offers FY20 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Biogen (BIIB) PT Lowered to $280 at RBC Capital
January 30, 2020 1:09 PM ESTRBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $280.00 (from $285.00) while maintaining a Sector Perform rating following results.
solid quarter and optimist guidanceremain on sidelines given adu risks and near-term IP/competitive threats to core franchises... More